Published in Hepatitis Weekly, January 23rd, 2006
XTL-6865 currently in a phase 1 clinical trial; XTL-2125 is pending the commencement of a phase 1 clinical trial.
The main component of the plan is a reduction in overall headcount of 13 employees, or approximately 25%. The workforce reduction is limited to employees based in the company's Rehovot, Israel, facility, and consists primarily of early stage research...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.